Mostrando ítems 1-2 de 2

Five insights from the Global Burden of Disease Study 2019

ABBAFATI, Cristiana; Abu-Gharbieh, Eman; adabi, maryam; Afarideh, Mohsen; Agarwal, Gina; Akombi-Inyang, Blessing; alicandro, gianfranco; Alonso, Jordi; Anderlini, Deanna; Alvis-Guzmán, Nelson; Andrei, Tudorel; Anvari, Davood; ARIPOV, TIMUR; Ashbaugh, Charlie; Babaee, Ebrahim; Balachandran, Arun; Baraki, Gebreegziabher; Bayati, Mohsen; Bhala, Neeraj; Brenner, Hermann; Brugha, Traolach; Castaldelli-Maia, Joao Mauricio; Charan, Dr. Jaykaran; Cislaghi, Beniamino Ferdinando; Cummins, Steven; Dandona, Rakhi; Deuba, Keshab; Edvardsson, David; eshrati, babak; Faro, Andre; Gallus, Silvano; ghadiri, keyghobad; Gorini, Giuseppe; Gupta, Rahul; Hassankhani, Hadi; Holla, Ramesh; Iavicoli, Ivo; Jalilian, Farzad; Kivimäki, Mika; Landires, Ivan; Mansouri, Borhan; mazidi, mohsen; Moradi, Ghobad; Perico, Norberto; Rabiee, Navid; Saddik, Basema; Schiavolin, Silvia; Schwendicke, Falk; Sharara, Fablina; Sulo, Gerhard; Thakur, Bhaskar; Touvier, Mathilde; Virvilaitė, Regina; Yuce, Deniz; Vos, Theo; Zhao, Yingxi (2020-10-17)

The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 provides a rules-based synthesis of the available evidence on levels and trends in health outcomes, a diverse set of risk factors, and health system ...
How expensive is treating patients in a center of excellence for rheumatoid arthritis in Colombia?

Alvis-Zakzuk, N. J.; Santos-Moreno, P.; Villarreal Peralta, L.; Alvis-Guzmán, N.; Carrasquilla, M. (Universidad de la Costa, 2019-05)

We aimed to estimate the cost of treating patients with rheumatoid arthritis (RA) in a Center of Excellence (CoE) for rheumatic diseases located in Bogotá, Colombia. We performed a cost analysis from the standard cost ...

Envíos recientes

Five insights from the Global Burden of Disease Study 2019
...
ABBAFATI, Cristiana | 2020-10-17

The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 provides a rules-based synthesis of the available evidence on levels and trends in health outcomes, a diverse set of risk factors, and health system responses. GBD 2019 covered 204 countries and territories, as well as first administrative level disaggregations for 22 countries, from 1990 to 2019. Because GBD is highly standardised and comprehensive, spanning both fatal and non-fatal outcomes, and uses a mutually exclusive and collectively exhaustive list of hierarchical disease and injury causes, the study provides a powerful basis for detailed and broad insights on global health trends and emerging challenges. GBD 2019 incorporates data from 281 586 sources and provides more than 3·5 billion estimates of health outcome and health system measures of interest for global, national, and subnational policy dialogue. All GBD estimates are publicly available and adhere to the Guidelines on Accurate and Transparent Health Estimate Reporting. From this vast amount of information, five key insights that are important for health, social, and economic development strategies have been distilled. These insights are subject to the many limitations outlined in each of the component GBD capstone papers.

LEER
How expensive is treating patients in a center of excellence for rheumatoid arthritis in Colombia?
...
Alvis-Zakzuk, N. J. | 2019-05

We aimed to estimate the cost of treating patients with rheumatoid arthritis (RA) in a Center of Excellence (CoE) for rheumatic diseases located in Bogotá, Colombia. We performed a cost analysis from the standard cost estimation of a CoE program for RA care. We estimated costs of consultations, laboratory and imaging tests, and pharmacological treatment from the measurement of the health care resource utilization of the CoE standard protocol according to the activity level of the disease (DAS28). Costing process was done following the recommendation of the Colombian Institute of Health Technology Assessment (IETS, in Spanish). Mean, minimum and maximum costs were reported annually for a type case depending on severity and classified as Remission, low disease activity (LDA), moderate disease activity (MDA) and severe disease activity -SDA- (with and without bDMARD). All costs were reported in American dollars, using the average exchange rate from January to December of 2018, reported by Banco de la República de Colombia: US$1 = $2,951.3 Colombian pesos. Mean total direct medical cost to treat a patient in remission is US$235.7 (213.0-336.4), in LDA is US325.2 (288.0-464.6) and in MDA is US$835.5 ($573.1-$2,187.1). There is a considerable increase in direct medical costs from a patient in SDA and SDA+Biologics: US$2,555.5 ($2,301.1-$3,890.9) to US$8,032.4 ($7,564.4-$8,400.3). The largest share of the cost was related to drugs, representing 39.9% for Remission, 53.6% for LDA, 75.2 for MDA, and in SDA and SDA+Biologics the proportion of what is spent on drugs for RA treatment is 88.5% and 96.7%, respectively. As the severity of the disease increases, the expenditure rate on drugs rises over the total of each activity level. With the introduction of the biological therapy, the treatment of RA is expensive, however, the CoE is an efficient way of care for RA.

LEER

Listar por tema "Arthritis"

Five insights from the Global Burden of Disease Study 2019 ﻿

How expensive is treating patients in a center of excellence for rheumatoid arthritis in Colombia? ﻿

Envíos recientes

Five insights from the Global Burden of Disease Study 2019

How expensive is treating patients in a center of excellence for rheumatoid arthritis in Colombia?

Five insights from the Global Burden of Disease Study 2019

How expensive is treating patients in a center of excellence for rheumatoid arthritis in Colombia?